期刊文献+

喉鳞癌组织Fas和FasL蛋白表达及临床意义 被引量:3

Expression and significance of Fas and FasL protein in squamous cell carcinoma of larynx
原文传递
导出
摘要 目的 :探讨Fas、FasL蛋白在喉鳞癌 (LSCC)组织中的表达及意义。方法 :采用SABC免疫组化法检测 4 2例LSCC及 2 0例手术切缘正常组织中Fas及FasL ,并与LSCC病理分级、临床分期及颈淋巴结转移相比较。结果 :Fas及FasL在LSCC中阳性率分别为 4 7.6 %和 6 4 .3% ,与在正常喉组织阳性率 90 .0 %和 2 0 .0 %相比 ,差异有显著性意义 (P <0 .0 5 )。Fas阳性率与肿瘤分级分期无显著相关性 (P >0 .0 5 ) ,与肿瘤转移有关 (P <0 .0 5 ) ;FasL阳性率与肿瘤分级、分期及转移密切相关 (P <0 .0 5 )。Fas与FasL的表达无显著相关性。结论 :Fas及FasL表达异常可能参与喉鳞癌的发生和发展 ;检测Fas与FasL可望作为判定喉鳞癌预后的潜在指标。 Objective:To investigate the expression of Fas and FasL protein in squamous cell carcinoma of larynx (LSCC) and to evaluate its clinical significance.Method:Using immunohistochemical method SABC, we studied the expression of Fas and FasL protein in 42 cases of paraffin embedded LSCC tissues and in 10 cases of normal laryngeal tissues. The positive rates of Fas and FasL were compared with the pathological grade, clinical stage and cervical lymph node metastasis of LSCC.Result:The positive rates of Fas and FasL protein staining were 47.6 % and 64.3 % in 42 cases with LSCC, while they were 90.0 % and 20.0 % in the normal laryngeal tissues(P< 0.05 ) respectively. Fas was not related to the tumor grade and tumor stage(P> 0.05 ). However, Fas was significantly related to the metastasis(P< 0.05 ).On the other hand, FasL was positively related to the tumor grade, clinical stage and the metastasis(P< 0.05 ).No significant correlation has been noted between Fas and FasL.Conclusion:The results suggest that the aberrant expression of Fas and FasL is closely related to the genesis and progression of LSCC. Fas and FasL might be a predictor for the prognosis of LSCC.
出处 《临床耳鼻咽喉科杂志》 CSCD 北大核心 2002年第12期661-662,共2页 Journal of Clinical Otorhinolaryngology
关键词 喉肿瘤 细胞凋亡 基因表达 免疫组织化学 Fas蛋白质 Laryngeal neoplasms Apoptosis Gene expression Immunohistochemistry Fas protein
  • 相关文献

参考文献4

  • 1Niehans G A,Brunner T,Frizeller S P,et al.Human lung carcinoma express Fas ligand[].Cancer Research.1997
  • 2Ungefroren H,Voss M,Jansen M,et al.Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis[].Cancer Research.1998
  • 3Gratas C,Tohma Y,Barnas C,et al.Up-regulation of Fas(APO-1/CD95)Ligand and down-regulation of Fas expression in human esophageal cancer[].Cancer Research.1998
  • 4Nagate S.Apoptosis by death factor[].Cell.1997

同被引文献23

  • 1向青,徐波,徐梅.Fas/FasL途径介导的人肺癌细胞免疫逃逸[J].中国病理生理杂志,2006,22(1):168-171. 被引量:15
  • 2姚鸿超,季文樾,关超,柳斌.肿瘤坏死因子相关凋亡诱导配体在喉癌中的表达[J].临床耳鼻咽喉科杂志,2006,20(24):1105-1108. 被引量:1
  • 3Nagate S. Apoptosis by death factor. Cell, 1997, 88: 355-365.
  • 4Lavrik IN, Golks A, Krammer PH. Caspases:pharmacological manipulation of cell death. J Clin Invest, 2005, 115: 2665-2672.
  • 5Sudarshan S, Holman DH, Hyer ML, et al. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. CancerGeneTher, 2005, 12: 12-18.
  • 6Kim R, Emi M, Tanabe K, et al. The role of Fas Ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer, 2004, 100: 2281-2291.
  • 7StrasserA, Jost P J, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity, 2009, 30: 180-192.
  • 8Yoo N J, Lee SH, Jeong EG, et al. Expression of nuclear and cytoplasmic phosphorylated FADD in gastric cancers. Pathol Res Pract, 2007, 203: 73-78.
  • 9Gibcus JH, Menkema L, Mastik MF, et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res, 2007, 13: 6257-6266.
  • 10Gibcus JH, Mastik MF, Menkema L, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer, 2008, 98: 950-955.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部